Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2010

01-03-2010 | Article

Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials

Authors: J. De Grijse, M. Asanghanwa, B. Nouthe, N. Albrecher, P. Goubert, I. Vermeulen, S. Van Der Meeren, K. Decochez, I. Weets, B. Keymeulen, V. Lampasona, J. Wenzlau, J. C. Hutton, D. Pipeleers, F. K. Gorus, the Belgian Diabetes Registry

Published in: Diabetologia | Issue 3/2010

Login to get access

Abstract

Aims/hypothesis

We investigated whether screening for insulinoma-associated protein (IA-2) beta (IA-2β) autoantibodies (IA-2βA) and zinc transporter-8 (ZnT8) autoantibodies (ZnT8A) improves identification of first-degree relatives of type 1 diabetic patients with a high 5-year disease risk, which to date has been based on assays for insulin autoantibodies (IAA), GAD autoantibodies (GADA) and IA-2 autoantibodies (IA-2A).

Methods

IA-2βA and ZnT8A (using a ZnT8 carboxy-terminal hybrid construct, CW-CR, carrying 325Arg and 325Trp) were determined by radiobinding assay in 409 IAA+, GADA+ and/or IA-2A+ siblings or offspring (<40 years) of type 1 diabetic patients consecutively recruited by the Belgian Diabetes Registry. The median (interquartile range) age of the first-degree relatives was 12 (6–19) years.

Results

Of the first-degree relatives, 24% were IA-2A+ (n = 97), 14% (n = 59) IA-2βA+ and 20% (n = 80) ZnT8A+. IA-2βA and ZnT8A were significantly (p < 0.001) associated with IA-2A and prediabetes (n = 86); in IA-2A− first-degree relatives (n = 312) the presence of IA-2βA and ZnT8A was associated with an increased progression rate to diabetes (p < 0.001). Positivity for IA-2A and/or ZnT8A emerged as the most sensitive combination of two markers to identify first-degree relatives with a 5-year progression rate to diabetes of 45% (survival analysis) and as strongest predictor of diabetes (Cox regression analysis). Omission of first-degree relatives protected by HLA-DQ genotypes or maternal diabetes reduced the group to be followed from n = 409 to n = 246 (40%) with minor loss in the number of prediabetic IA-2A+ or ZnT8A+ first-degree relatives identified (n = 3).

Conclusions/interpretation

IA-2A+ and/or ZnT8A+ first-degree relatives may be the participants of choice in future secondary prevention trials with immunointervention in relatives of type 1 diabetic patients.
Appendix
Available only for authorised users
Literature
1.
Keymeulen B, Vandemeulebroucke E, Ziegler A et al (2005) Insulin needs following CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608CrossRefPubMed
2.
Vandemeulebroucke E, Keymeulen B, Decochez K et al (2009) Hyperglycaemic clamp test for diabetes risk assessment in IA-2 antibody-positive relatives of type 1 diabetic patients. Diabetologia. doi:10.​1007/​s00125-009-1569-3 PubMed
3.
Chatenoud L, Thervet E, Primo J, Bach JF (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91:123–127CrossRefPubMed
4.
Gorus FK, Pipeleers DG (2001) Prospects for predicting and stopping the development of type 1 diabetes. Best Pract Res Clin Endocrinol 15:371–389CrossRef
5.
Verge CF, Gianani R, Kawasaki E et al (1996) Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD and ICA 512bdc/IA-2 autoantibodies. Diabetes 45:926–933CrossRefPubMed
6.
Kulmala P, Savola K, Petersen JS et al (1998) Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. J Clin Invest 101:327–336CrossRefPubMed
7.
Notkins AL, Lernmark Å (2001) Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 108:1247–1252PubMed
8.
Bingley PJ, Gale EA (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49:881–890CrossRefPubMed
9.
Gorus FK, Goubert P, Semakula C et al (1997) IA-2 autoantibodies complement GAD65-autoantibodies in new onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry. Diabetologia 40:95–99CrossRefPubMed
10.
Decochez K, De Leeuw I, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients. The Belgian Diabetes Registry. Diabetologia 45:1658–1666CrossRefPubMed
11.
Achenbach P, Warncke K, Reiter J et al (2004) Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 53:384–392CrossRefPubMed
12.
Achenbach P, Bonifacio E, Williams AJ et al (2008) Autoantibodies to IA-2 beta improve diabetes risk assessment in high-risk relatives. Diabetologia 51:488–492CrossRefPubMed
13.
Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8A (Sec 30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040–17045CrossRefPubMed
14.
Wenzlau JM, Liu Y, Yu L et al (2008) A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 57:2693–2697CrossRefPubMed
15.
Kawasaki E, Uga M, Nakamura K et al (2008) Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes. Diabetologia 51:2299–2302CrossRefPubMed
16.
Decochez K, Truyen I, Van der Auwera B et al (2005) Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 48:687–694CrossRefPubMed
17.
Vandewalle CL, Coeckelberghs MI, De Leeuw IH et al (1997) Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. Diabetes Care 20:1556–1561CrossRefPubMed
18.
Van der Auwera BJ, Schuit FC, Weets I et al (2002) Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for further prevention studies. Hum Immunol 63:40–50CrossRefPubMed
19.
Vandewalle CL, Falorni A, Svanholm S et al (1995) High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. J Clin Endocrinol Metab 80:846–851CrossRefPubMed
20.
Hämäläinen AM, Knip M (2002) Autoimmunity and familial risk of type 1 diabetes. Curr Diab Rep 2:347–353CrossRefPubMed
21.
Christie MR, Genovese S, Cassidy D et al (1994) Antibodies to islet 37 k antigen, but not to glutamate decarboxylase discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 43:1254–1259CrossRefPubMed
22.
Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 52:1881–1888CrossRefPubMed
23.
Solimena M, Dirkx R Jr, Hermel JM et al (1996) ICA512, an autoantigen of type 1 diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J 15:2102–2114PubMed
24.
Wasmeier C, Hutton JC (1996) Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem 271:18161–18170CrossRefPubMed
25.
Chimienti F, Devergnas S, Favier A, Seve M (2004) Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 53:2330–2337CrossRefPubMed
26.
Lampasona V, Bearzatto M, Genovese S et al (1996) Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol 157:2707–2711PubMed
27.
Notkins AL, Zhang B, Matsumoto Y, Lan MS (1997) Comparison of IA-2 with IA-2beta and with six other members of the protein tyrosine phosphatase family: recognition of antigenic determinants by IDDM sera. J Autoimmun 10:245–250CrossRefPubMed
28.
Yu L, Rewers M, Gianani R et al (1996) Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab 81:4264–4267CrossRefPubMed
29.
Leslie RDG, Delli Castelli M (2004) Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53:3033–3040CrossRefPubMed
30.
Achenbach P, Bonifacio E, Koczwara K, Ziegler AG (2005) Natural history of type 1 diabetes. Diabetes 54(Suppl 2):S25–S31CrossRefPubMed
31.
Truyen I, De Pauw P, Jørgensen P et al (2007) Proinsulin level and proinsulin-to-C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 48:2322–2329CrossRef
32.
Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692–1698CrossRefPubMed
Metadata
Title
Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials
Authors
J. De Grijse
M. Asanghanwa
B. Nouthe
N. Albrecher
P. Goubert
I. Vermeulen
S. Van Der Meeren
K. Decochez
I. Weets
B. Keymeulen
V. Lampasona
J. Wenzlau
J. C. Hutton
D. Pipeleers
F. K. Gorus
the Belgian Diabetes Registry
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1618-y

Other articles of this Issue 3/2010

Diabetologia 3/2010 Go to the issue

Article

Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis

Article

Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)

Article

Case fatality rates after first acute coronary syndrome in persons treated for type 2 diabetes show an improving trend

Review

Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective

Article

Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle

Commentary

IL6 as a mediator of insulin resistance: fat or fiction?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits